S. Munir Ahmad

An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma

I. Svane, A. O. Gang, Ö. Met, 2021, OncoImmunology.

Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment

I. Svane, Ö. Met, M. Carretta, 2022, Oncoimmunology.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.

B. Seliger, T. Schumacher, M. V. van Buuren, 2017, Cancer research.

Frequent adaptive immune responses against arginase-1

M. Donia, I. Svane, R. Mortensen, 2018, Oncoimmunology.

PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine

M. Donia, I. Svane, T. Borch, 2016, Oncoimmunology.

Staphylococcus aureus alpha-toxin inhibits CD8+ T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma

J. Becker, R. Clark, C. Geisler, 2020, Oncoimmunology.

CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment

M. Donia, I. Svane, T. Klausen, 2016, Oncoimmunology.